Objective To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy(MCT) and transcatheter arterial chemoembolization(TACK) in patients with recurrent hepatocelluar carcinoma. Methods From January 2007 to January 2011, 94 patients with recurrent hepatocelluar carcinoma(HCC) were treated with MCT and TACE in the peoples hospital of Guangdong province. The treatment group received sorafenib + MCT + TACE, and the control group received MCT + TACE. Results RR of the treatment group was 68. 2% , which of the control group was 56. 3%(x2 = 1. 12,P>0. 05). DCR was 84. 1% in the treatment group and 68. 8% in the control group(x2 = 16. 214,P<0. 05). Through a comparison of survival curves along with the extension of time, the survival rates of two groups were decreased, but the treatment group (group 1) had a significantly higher survival rate than the control group(group 2) , with a statistically significant difference(t = 2. 242,P<0. 05). Conclusion Sorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC.%目的 探讨索拉非尼联合微波消融(MCT)和经皮肝动脉插管化疗栓塞(TACE)治疗复发性肝细胞癌患者的疗效.方法 94例复发性肝细胞癌患者,其中44例采用索拉非尼+MCT+TACE治疗(治疗组),50例行MCT+TACE治疗(对照组),比较两组患者的疗效、生存状况和不良反应.率的比较采用χ2检验.结果 治疗组患者的有效率为68.2%,与对照组56.3%比较,差异无统计学意义(χ2=1.12,P>0.05).治疗组患者的疾病控制率为84.1%,高于对照组的68.8%(χ2=16.214,P<0.05).治疗组患者的生存时间为6~29个月,中位生存时间为19.5个月;对照组患者的生存时间为5~23个月,中位生存时间为11.3个月,两组比较,差异有统计学意义(t=2.242,P<0.05).治疗组患者腹泻、手足综合征、皮疹的发生率均高于对照组,差异均有统计学意义(χ2=6.782、12.253、16.421,均P<0.05);两组患者疲劳、消化道反应、骨髓抑制、肝功能异常的发生率,差异均无统计学意义(χ2=1.981、2.456、0.464、0.517,均P>0.05).结论 索拉非尼联合MCT和TACE治疗能控制复发性肝细胞癌患者的疾病发生率,提高生存率.
展开▼
